Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Increasing effectiveness of interferon-alpha for malignancies

D J Lindner1, D V Kalvakolanu, E C Borden

  • 1Department of Microbiology/Immunology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore 21201, USA.

Seminars in Oncology
|June 1, 1997
PubMed
Summary

Alpha-interferons (IFN-alphas) show effectiveness in treating cancers and improving survival. Preclinical data suggest synergistic effects between IFN-alpha2 and antiestrogens like toremifene and tamoxifen against tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
Same author

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Leukemia·2014
Same author

GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis.

Oncogene·2013
Same author

Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC.

Cancer gene therapy·2012
Same author

A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Oncogene·2012
Same author

G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.

Oncogene·2011

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Alpha-interferons (IFN-alphas) are effective in treating various cancers, including leukemias, lymphomas, and solid tumors.
  • IFN-alphas are the first therapeutic proteins to demonstrate increased survival in cancer patients.
  • Interferons possess pleiotropic activities, suggesting potential synergistic interactions with other anticancer agents.

Purpose of the Study:

  • To explore the potential synergistic antitumor interactions between IFN-alpha2 and antiestrogens.
  • To investigate the molecular basis of synergistic interactions between interferons and antiestrogens.
  • To identify the role of IFN-stimulated genes in mediating synergistic anticancer effects.

Main Methods:

  • Preclinical in vitro studies.

Related Experiment Videos

  • Animal model studies.
  • Analysis of IFN-stimulated genes.

    • Main Results:

    • Preclinical data indicate a synergistic antitumor interaction between IFN-alpha2 and the antiestrogens toremifene and tamoxifen.
    • Evidence suggests that interferons can enhance the efficacy of antiestrogen therapies.

    Conclusions:

    • IFN-alpha2 in combination with toremifene or tamoxifen demonstrates synergistic antitumor activity.
    • Further research is needed to fully understand the molecular mechanisms underlying these synergistic interactions, particularly the role of IFN-stimulated genes.